Journal for ImmunoTherapy of Cancer shared on X/Twitter:

“Meet the Author: Amin H. Nassar, a medical oncology fellow from Yale Cancer Center, is co-1st author of ‘Clinical Outcomes and Safety of Immune Checkpoint Inhibitors in Patients with Solid Tumors and Paraneoplastic Syndromes,’ recently published in JITC!
1/6

Dr. Nassar was inspired to become a researcher by the remarkable advancements made in cancer treatment. He is motivated to contribute knowledge that enables future breakthroughs and treatment innovations and he hopes to make a tangible difference for those living with cancer.
2/6

He is most excited about the possibility of reprogramming tumors to enhance immune recognition and killing. He is pursuing a career as a physician-scientist and hopes to find ways to genetically reprogram ‘cold’ tumors into ‘hot’ ones.
3/6

He will be graduating as a medical oncology fellow next year (clinical focus in thoracic oncology) and plans to apply for physician-scientist positions with a focus on tumor immunology.
4/6

He is proud to publish in JITC because ‘JITC provides state-of-the-art research in the field of immunology. The review process is rigorous and well-structured.’
5/6

Outside of research, Dr. Nassar loves soccer and board games! You can always count on him for a game of Catan.

Read his recent work here.
6/6″

Source: Journal for ImmunoTherapy of Cancer/X